Advanced Filters
noise

Bala-Cynwyd, Pennsylvania Clinical Trials

A listing of Bala-Cynwyd, Pennsylvania clinical trials actively recruiting patient volunteers.

Found 1,618 clinical trials

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

18 years of age Male Phase 3
J Jessica Spahn, MS, ACSM-CEP, ACSM-CPT

Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

The goal of this clinical trial is to test in moderately symptomatic chronic subdural hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an alternative to conventional open surgery. The main questions it aims to answer are: Compared to open conventional surgery, does MMAE reduce the …

40 - 90 years of age All Phase N/A
A Aditya Parikh, MD

Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure

RECOVER HF is a clinical study designed to evaluate the safety and efficacy of Synchronized Diaphragmatic Stimulation delivered using the VisONE System in the treatment of patients with heart failure.

18 years of age All Phase N/A
A Alyrene Dorey, MD

Standard Versus High Dose ED-Initiated Buprenorphine Induction

This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post randomization, and opioid withdrawal symptoms, opioid …

18 - 65 years of age All Phase 3

Assessment of Geriatric Evaluations Impact on New AML Guidance

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information …

50 years of age All Phase N/A
M Meghan Rys, MS, CCRP

Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients

This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.

5 - 25 years of age All Phase 0
M Mark Klein

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first …

18 years of age Male Phase 2
T Tamara Riesgo

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

This study will evaluate the safety and efficacy of ATSN-201 in subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).

6 years of age All Phase 3
G Geraldine Liu, MA

Evaluation of Outcome Metrics in Alexander Disease

The purpose of this study is to define the natural history of Alexander Disease, a leukodystrophy that causes neurological dysfunction. Investigators will obtain clinical outcome assessments to measure how the disease affects a patient's gross motor, fine motor, speech and language function, swallowing, and quality of life. Specimens are collected …

years of age All Phase N/A
C Courtney Brown, RN

Phase IB/II of CPX-351 for Relapse Prevention in AML

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days pending toxicity. …

18 years of age All Phase 1/2

Simplify language using AI